Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells

9 Sept 2016

Abstract excerpt

BACKGROUND: Mutations in DNA damage response factors BRCA1 and BRCA2 confer sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors in breast and ovarian cancers. BRCA1/BRCA2-defective tumors can exhibit resistance to PARP inhibitors via multiple mechanisms, one of which involves loss of 53BP1. Deficiency in the DNA damage response factor ataxia-telangiectasia mutated (ATM) can also sensitize tumors to PARP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27613518
DOI: 10.1186/s12885-016-2754-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cellsPMID 27613518Read ↗

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic ApproachesSemantic proximity Read ↗

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity Read ↗

PARP inhibitors in breast cancer: BRCA and beyond.Semantic proximity Read ↗

PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.Semantic proximity Read ↗

Therapeutic Targeting of DNA Damage Response Pathways in TP53 - and ATM -Mutated TumorsSemantic proximity Read ↗

PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments.Semantic proximity Read ↗

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatmentSemantic proximity Read ↗

Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cellsSemantic proximity Read ↗

ATM-Deficient Cancers Provide New Opportunities for Precision OncologySemantic proximity Read ↗

Modulation of Early Mitotic Inhibitor 1 (EMI1) Depletion on the Sensitivity of PARP Inhibitors in BRCA1 Mutated Triple-Negative Breast Cancer CellsSemantic proximity Read ↗

ATM-depletion in breast cancer cells confers sensitivity to PARP inhibitionSemantic proximity Read ↗

The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.